David Chang Sells 47,763 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics CEO David Chang sold 47,763 shares of the company’s stock on March 16th, reducing his stake by 0.92%. The transaction, valued at over $117,000, leaves him with approximately 5.15 million shares. Despite the insider selling, analysts maintain a “Moderate Buy” rating for ALLO with an average price target of $8.50, and the company recently beat EPS estimates.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin